SCHEMBL7419767

SCHEMBL7419767

COc1ccc(C)cc1S(=O)(=O)N[C@@H](Cc1ccc(OCCCONC(=N)N)cc1)C(=O)OC(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
F2 P00734 1/20 0.38
KMT2A Q03164 4/20 0.38
ITGB3 P05106 5/20 0.37
ITGA2B P08514 2/20 0.37
ITGAV P06756 3/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
PPARG P37231 2/20 0.36
ITGB1 P05556 1/20 0.35
ITGA5 P08648 1/20 0.35
HPGD P15428 1/20 0.35
MEN1 O00255 2/20 0.35
POLB P06746 1/20 0.34
TP53 P04637 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7415180 0.94 CYP3A4 (0.45) CYP3A4CYP2C19ITGB3ITGA2BITGAV
SCHEMBL7414783 0.92 CYP3A4 (0.43) CYP3A4CYP2C19KMT2AITGB3ITGA2B
SCHEMBL7418892 0.92 CYP3A4 (0.43) CYP3A4CYP2C19KMT2AITGB3ITGA2B
SCHEMBL7410416 0.92 L3MBTL1 (0.41) CYP3A4CYP2C19F2KMT2AITGB3
Trifluoroacetic Acid SCHEMBL7419764 0.90 CYP3A4 (0.47) CYP3A4CYP2C19F2KMT2AITGB3
SCHEMBL7416867 0.88 NPSR1 (0.40) CYP3A4CYP2C19F2KMT2AITGB3
SCHEMBL7695352 0.87 ITGB3 (0.49) CYP3A4CYP2C19F2KMT2AITGB3
SCHEMBL7422540 0.87 ITGB3 (0.42) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL7416574 0.86 ITGB3 (0.45) F2ITGB3ITGA2BITGAVITGB1
SCHEMBL7412260 0.86 AVPR1A (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6344484-B1 TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-02-05 US disclosed
EP-1159262-A1 TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-12-05 EP disclosed
WO-2000047552-A1 TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed